Literature DB >> 10780975

Neuropeptide Y regulates intracellular calcium through different signalling pathways linked to a Y(1)-receptor in rat mesenteric small arteries.

D Prieto1, C L Buus, M J Mulvany, H Nilsson.   

Abstract

Simultaneous measurements of intracellular calcium concentration ([Ca(2+)](i)) and tension were performed to clarify whether the mechanisms which cause the neuropeptide Y (NPY)-elicited contraction and potentiation of noradrenaline contractions, and the NPY inhibition of forskolin responses are linked to a single or different NPY receptor(s) in rat mesenteric small arteries. In resting arteries, NPY moderately elevated [Ca(2+)](i) and tension. These effects were antagonized by the selective Y(1) receptor antagonist, (R)-N(2)-(diphenacetyl)-N-[(4-hydroxyphenyl)methyl]-D-argininea mide (BIBP 3226) (apparent pK(B) values of 8.54+/-0.25 and 8.27+/-0.17, respectively). NPY (0.1 microM) caused a near 3 fold increase in sensitivity to noradrenaline but did not significantly modify the tension-[Ca(2+)](i) relationship for this agonist. BIBP 3226 competitively antagonized the contractile response to NPY in arteries submaximally preconstricted with noradrenaline (pA(2) 7.87+/-0.20). In arteries activated by vasopressin, the adenylyl cyclase activator forskolin (3 microM) induced a maximum relaxation and a return of [Ca(2+)](i) to resting levels. NPY completely inhibited these effects. The contractile responses to NPY in arteries maximally relaxed with either sodium nitroprusside (SNP) or nifedipine were not significantly higher than those evoked by the peptide at resting tension, in contrast to the contractions to NPY in forskolin-relaxed arteries. BIBP 3226 competitively antagonized the contraction to NPY in forskolin-relaxed arteries with a pA(2) of 7.92+/-0.29. Electrical field stimulation (EFS) at 8-32 Hz caused large contractions in arteries relaxed with either forskolin or noradrenaline in the presence of phentolamine. These responses to EFS were inhibited by BIBP 3226. Similar EFS in resting, non-activated arteries did not produce any response. The present results suggest that different intracellular pathways are linked to a single NPY Y(1) receptor in intact rat mesenteric small arteries, and provide little support for involvement of other postjunctional NPY receptors in the contractile responses to NPY. Neurally released NPY also seems to act through Y(1) receptors, and may serve primarily as an inhibitor of vasodilatation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10780975      PMCID: PMC1572012          DOI: 10.1038/sj.bjp.0703256

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Neuropeptide YY1 receptors-mediated increase in intracellular Ca2+ concentration via phospholipase C-dependent pathway in porcine aortic smooth muscle cells.

Authors:  Y Shigeri; S Nakajima; M Fujimoto
Journal:  J Biochem       Date:  1995-09       Impact factor: 3.387

2.  The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226.

Authors:  K Rudolf; W Eberlein; W Engel; H A Wieland; K D Willim; M Entzeroth; W Wienen; A G Beck-Sickinger; H N Doods
Journal:  Eur J Pharmacol       Date:  1994-12-27       Impact factor: 4.432

Review 3.  Neuropeptide Y effector systems: perspectives for drug development.

Authors:  L Grundemar; R Håkanson
Journal:  Trends Pharmacol Sci       Date:  1994-05       Impact factor: 14.819

4.  Possible location and function of neuropeptide Y receptor subtypes in the rat mesenteric arterial bed.

Authors:  M A McAuley; T C Westfall
Journal:  J Pharmacol Exp Ther       Date:  1992-06       Impact factor: 4.030

5.  Norepinephrine and neuropeptide Y increase intracellular Ca2+ in cultured porcine aortic smooth muscle cells.

Authors:  W Erdbrügger; P Vischer; H J Bauch; M C Michel
Journal:  J Cardiovasc Pharmacol       Date:  1993-07       Impact factor: 3.105

6.  Cyclic AMP relaxes swine arterial smooth muscle predominantly by decreasing cell Ca2+ concentration.

Authors:  N L McDaniel; C M Rembold; H M Richard; R A Murphy
Journal:  J Physiol       Date:  1991-08       Impact factor: 5.182

7.  Minor role for direct adrenoceptor-mediated calcium entry in rat mesenteric small arteries.

Authors:  H Nilsson; P E Jensen; M J Mulvany
Journal:  J Vasc Res       Date:  1994 Nov-Dec       Impact factor: 1.934

8.  Neuropeptide Y increases force development through a mechanism that involves calcium entry in resistance arteries.

Authors:  R Andriantsitohaina; K Bian; J C Stoclet; R D Bukoski
Journal:  J Vasc Res       Date:  1993 Nov-Dec       Impact factor: 1.934

9.  Ca2+ handling mechanisms underlying neuropeptide Y-induced contraction in canine basilar artery.

Authors:  Y Tanaka; T Nakazawa; H Ishiro; M Saito; H Uneyama; S Iwata; K Ishii; K Nakayama
Journal:  Eur J Pharmacol       Date:  1995-03-15       Impact factor: 4.432

10.  Synergistic interaction of Y1-neuropeptide Y and alpha 1b-adrenergic receptors in the regulation of phospholipase C, protein kinase C, and arachidonic acid production.

Authors:  L A Selbie; K Darby; C Schmitz-Peiffer; C L Browne; H Herzog; J Shine; T J Biden
Journal:  J Biol Chem       Date:  1995-05-19       Impact factor: 5.157

View more
  10 in total

1.  Rat mesenteric small artery neurogenic dilatation is predominantly mediated by β1 -adrenoceptors in vivo.

Authors:  Asger Maare Søndergaard; Cathrine Bang Overgaard; Aleksandra Mazur; Dmitry D Postnov; Vladimir V Matchkov; Christian Aalkjaer
Journal:  J Physiol       Date:  2019-02-21       Impact factor: 5.182

2.  Neuropeptide Y2 receptors are involved in enhanced neurogenic vasoconstriction in spontaneously hypertensive rats.

Authors:  Kathryn A Gradin; Carsten L Buus; Jia-Yi Li; Ole Frøbert; Ulf Simonsen
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

3.  Heterogeneity of the neuropeptide Y (NPY) contractile and relaxing receptors in horse penile small arteries.

Authors:  Dolores Prieto; Luis Rivera de Los Arcos; Pilar Martínez; Sara Benedito; Albino García-Sacristán; Medardo Hernández
Journal:  Br J Pharmacol       Date:  2004-11-22       Impact factor: 8.739

4.  Vanilloid receptors mediate adrenergic nerve- and CGRP-containing nerve-dependent vasodilation induced by nicotine in rat mesenteric resistance arteries.

Authors:  Shinji Eguchi; Satoko Tezuka; Narumi Hobara; Shinji Akiyama; Yuji Kurosaki; Hiromu Kawasaki
Journal:  Br J Pharmacol       Date:  2004-07-12       Impact factor: 8.739

5.  Prenatal stress in the rat results in increased blood pressure responsiveness to stress and enhanced arterial reactivity to neuropeptide Y in adulthood.

Authors:  Natalia Igosheva; Paul D Taylor; Lucilla Poston; Vivette Glover
Journal:  J Physiol       Date:  2007-05-10       Impact factor: 5.182

6.  Receptors for NPY and PACAP differ in expression and activity during adipogenesis in the murine 3T3-L1 fibroblast cell line.

Authors:  Martin T Gericke; Joanna Kosacka; Daniela Koch; Marcin Nowicki; Thomas Schröder; Albert M Ricken; Karen Nieber; Katharina Spanel-Borowski
Journal:  Br J Pharmacol       Date:  2009-04-27       Impact factor: 8.739

7.  Regional variation in electrically-evoked contractions of rabbit isolated pulmonary artery.

Authors:  V Margaret Jackson; Stephen J Trout; Tom C Cunnane
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

8.  Sympathetic neurogenic Ca2+ signalling in rat arteries: ATP, noradrenaline and neuropeptide Y.

Authors:  W Gil Wier; Wei-Jin Zang; Christine Lamont; Hema Raina
Journal:  Exp Physiol       Date:  2008-10-17       Impact factor: 2.969

9.  ZP120 causes relaxation by pre-junctional inhibition of noradrenergic neurotransmission in rat mesenteric resistance arteries.

Authors:  U Simonsen; B E Laursen; J S Petersen
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

Review 10.  DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.

Authors:  Jianqiang Zhang; Qiuyue Chen; Jixin Zhong; Chaohong Liu; Bing Zheng; Quan Gong
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.